{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:09:12Z","timestamp":1773875352130,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The landscape of treatment for\u00a0multiple myeloma\u00a0(MM) has significantly changed over the last decade due to\u00a0novel agents\u00a0that\u00a0have shown superiority in efficacy such as proteasome inhibitors (PIs)\u00a0and\u00a0immunomodulatory drugs\u00a0(IMiDs)\u00a0over traditional therapies.\u00a0However,\u00a0the real\u2010world utilization of these new agents\u00a0has\u00a0not been studied well.\u00a0This study evaluated year\u2010to\u2010year changes in treatment choices in a cohort of patients aged 66 or older in the Surveillance, Epidemiology, and End Results (SEER) registry linked with Medicare claims (SEER\u2010Medicare) data who were diagnosed with MM between 2007 and 2011.\u00a0We identified 2477\u00a0symptomatic\u00a0newly diagnosed\u00a0patients\u00a0who were followed for 6\u00a0months or more postdiagnosis and treated with systemic therapies but not with stem cell transplantation. Symptomatic patients were identified by evidence of hypercalcemia, renal failure, anemia, or bone lesions (CRAB criteria). The minimum follow\u2010up was imposed to ensure sufficient data to characterize treatment. Our analysis found that\u00a0the\u00a0proportion\u00a0of\u00a0treated patients\u00a0increased from\u00a075%\u00a0in the\u00a02007\u00a0cohort\u00a0to\u00a079%\u00a0in\u00a0the\u00a02011\u00a0cohort.\u00a0The share of PI\u2010based regimens including\u00a0PI plus alkylating agents, PI\u00a0plus\u00a0IMiD, and PI\u2010only increased from 9% to 21%, 3% to 11%, and 16%\u00a0to\u00a022%, respectively,\u00a0between 2007 and 2011.\u00a0These findings translate to the\u00a0share of PI\u2010based\u00a0regimens\u00a0having increased\u00a0from 28% to 55%\u00a0and\u00a0that of\u00a0IMiDs\u2010based\u00a0regimens\u00a0(excluding PI\u00a0plus\u00a0IMiD)\u00a0having decreased\u00a0from\u00a043%\u00a0to\u00a027%.\u00a0In\u00a0conclusion,\u00a0while\u00a0the\u00a0usage of\u00a0PIs\u00a0among elderly\u00a0MM\u00a0patients\u00a0increased significantly replacing\u00a0IMiD\u2010based regimens\u00a0(with or without alkylating agents but not with PI)\u00a0between 2007 and 2011,\u00a0this significant shift\u00a0did\u00a0not\u00a0increase\u00a0the\u00a0proportion of treated patients.<\/jats:p>","DOI":"10.1002\/cam4.2698","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T19:51:23Z","timestamp":1575489083000},"page":"626-639","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front\u2010line regimens using the SEER\u2010Medicare data"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-3851","authenticated-orcid":false,"given":"Daisuke","family":"Goto","sequence":"first","affiliation":[{"name":"Merck Research Laboratories North Wales PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-0431","authenticated-orcid":false,"given":"Rahul","family":"Khairnar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-6299","authenticated-orcid":false,"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Maryland School of Medicine Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-0720","authenticated-orcid":false,"given":"Candice","family":"Yong","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP Gaithersburg MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-7589","authenticated-orcid":false,"given":"Dorothy","family":"Romanus","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberechukwu","family":"Onukwugha","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-9220","authenticated-orcid":false,"given":"Julia F.","family":"Slejko","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Health Services Research University of Maryland School of Pharmacy Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4600"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2008.14.S7-A.12"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298760"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002493"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0113"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.12.002"},{"key":"e_1_2_7_9_1","unstructured":"SEER cancer stat facts: Myeloma.Bethesda MD:National Cancer Institute.https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 03\/28 2017."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.110296"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32405-9"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70187-X"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0061"},{"key":"e_1_2_7_15_1","unstructured":"National Cancer Institute.A to Z list of cancer drugs.https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs. Updated 2017.Accessed 06\/01 2017."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-358812"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019778"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.8.831"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.346"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70068-1"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341669"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61537-2"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.2114"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2014.434"},{"key":"e_1_2_7_29_1","unstructured":"National cancer institute.SEER\u2010medicare linked database.https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/. Updated 2017.Accessed 06\/01 2017."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0047-5"},{"key":"e_1_2_7_31_1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma vol 4.2018.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf.Accessed February 17 2018."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1555460"},{"issue":"2","key":"e_1_2_7_34_1","first-page":"152","article-title":"Prolonged duration of therapy is associated with improved survival in patients treated for relapsed\/refractory multiple myeloma in routine clinical care in the United States","volume":"18","author":"Hari P","year":"2018","journal-title":"CLML"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12606"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2017.09.007"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90129-5"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2009.02355.x"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.2307\/1910997"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.013"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2011.03.005"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.04.001"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.173"},{"key":"e_1_2_7_44_1","doi-asserted-by":"crossref","unstructured":"FouquetG GayF BoyleE et al.Treatment of newly diagnosed elderly multiple myeloma. In: Plasma cell dyscrasias.Springer;2016:123\u2010143.","DOI":"10.1007\/978-3-319-40320-5_8"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2546"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002493"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.2698","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2698","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2698","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T11:14:09Z","timestamp":1756120449000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1002\/cam4.2698"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2698","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,4]]},"assertion":[{"value":"2019-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}